Decheng Capital’s Revolution Medicines RVMD Stock Holding History

Decheng Capital’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.86M	Sell	52,667 -40,833	-44%	-$5.96M	1.35%	8
2026 Q1	$9.09M	Sell	93,500 -106,500	-53%	-$10.8M	1.38%	9
2025 Q4	$15.9M	Sell	200,000 -10,000	-5%	-$656K	2.14%	7
2025 Q3	$9.81M	Sell	210,000 -16,000	-7%	-$626K	1.71%	7
2025 Q2	$8.31M	Hold	226,000	–	–	2.1%	10
2025 Q1	$7.99M	Hold	226,000	–	–	2.24%	7
2024 Q4	$9.89M	Buy	226,000 +224,000	+11,200%	+$11.3M	2.12%	8
2024 Q3	$90.7K	Buy	+2,000	New	+$87.1K	0.02%	25

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Decheng Capital's RVMD Position: Q2 2026 in Review

Decheng Capital reduced its Revolution Medicines (RVMD) stake by 44% in Q2 2026, selling an estimated $5.96M and leaving 52,667 shares worth $9.86M. The position accounts for 1.35% of the portfolio, ranked #8.

Decheng Capital first reported a position in RVMD in Q3 2024 and has held it in 8 quarters since. The position peaked at $15.9M in Q4 2025. 688 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Decheng Capital held 52,667 shares of Revolution Medicines worth $9.86M as of Q2 2026.
Decheng Capital sold 40,833 Revolution Medicines shares in Q2 2026, an estimated $5.96M.
Revolution Medicines made up 1.35% of Decheng Capital's portfolio in Q2 2026, its #8 holding.
Decheng Capital first reported a position in Revolution Medicines in Q3 2024 and has held it in 8 quarters since.
Decheng Capital's Revolution Medicines position peaked at $15.9M in Q4 2025.
688 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Decheng Capital's 13F filing for Q2 2026, filed 14 Aug 2026.